Mediar Therapeutics has announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Bristol Myers Squibb, Eli Lilly & Company, Mass General Brigham Ventures and others. Mediar is advancing a portfolio of first-in-class therapies that halt and even reverse […]

Epigenetic editing pioneer Chroma Medicine has completed a $135 million Series B financing from a syndicate of investors led by GV (Google Ventures). The financing will support advancement of Chroma’s therapeutic programs toward the clinic and continued investment in the company’s core epigenetic editing platform. “In the year since launch, we have made significant progress […]

Boston-based SmartLabs, developer of “Managed Research Centers,” is launching a new research, development, office and related production center at the CambridgeSide mall. Set to open in late 2024. the complex will be SmartLabs’ most advanced facility to date, according to its website. The new facility will join SmartLabs’ four existing Managed Research Centers in Cambridge […]

Boston’s Aera Therapeutics announced its launch last month with $193 million in combined Series A and B financings and a vision to harness its proprietary delivery platform to “unlock the potential of genetic medicines across a wide range of modalities and therapeutic areas.” Aera’s delivery platform is designed to address the limitations of today’s delivery […]

Moderna and Life Edit Therapeutics, an ElevateBio company based in Durham, NC, are forming a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary gene editing technologies, including base editing, with Moderna’s mRNA platform to advance in vivo gene editing therapies against a select […]

Lexington’s Frequency Therapeutics has announced that the Phase 2b study of its hearing loss therapy FX-322 has failed to meet its primary endpoint. As a result, the company will discontinue the FX-322 development program along with a related program. Frequency’s efforts will now focus on continuing to develop novel therapeutics to induce remyelination for individuals […]

Collaboration partners Sage Therapeutics and Biogen have announced that the FDA has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational drug being evaluated as a 14-day, rapid-acting, once-daily, oral treatment in adults with MDD and PPD. The […]

Joined by a coalition of local legislators, including state Sen. Jamie Eldridge and members of the Devens Enterprise Commission, the $1.4 billion French biotech and pharmaceutical giant celebrated the completion of and move to a “state-of-the-art” research and development facility at 67 Buena Vista Street, replacing a smaller facility on Jackson Road. Seqens President and […]

French drugmaker Ipsen plans to acquire Cambridge-based Albireo in a deal worth about $952 million. Albierio is developing bile-acid modulators to treat pediatric and adult cholestatic liver diseases. The company was spun out from AstraZeneca in 2008 and is headquartered in Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The anticipated acquisition will enrich […]

The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, have announced discontinuation of its HIV vaccine Phase 3 clinical trial based on the results of an independent data review by the study’s independent Data and Safety Monitoring Board (DSMB). The review determined that the HIV vaccine regimen was not […]